The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research ... Additionally, the recent acquisition of Scorpion by Lilly for a significant sum ...
Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials for breast cancer and other advanced solid tumours. GSK flagged the US$1.15 ...
Drug developers Aardvark Therapeutics, Aurion Biotech, Sonna Therapeutics, Metsera, and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Maze ...
TransCode Therapeutics (RNAZ) shares are rising after dosing the first patient in Cohort 3 of its Phase 1 trial for lead candidate TTX-MC138 No significant safety issues were reported in previous ...
09:49 EST Transcode Therapeutics (RNAZ) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
